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Abstract
Prader–Willi syndrome (PWS) is a neurodevelopmental disorder caused by deletion or inactivation of paternally expressed
imprinted genes on human chromosome 15q11–q13. In addition to endocrine and developmental issues, PWS presents with
behavioural problems including stereotyped behaviour, impulsiveness and cognitive deficits. The PWS genetic interval
contains several brain-expressed small nucleolar (sno) RNA species that are subject to genomic imprinting, including
snord115 that negatively regulates post-transcriptional modification of the serotonin 2C receptor (5-HT2CR) pre-mRNA
potentially leading to a reduction in 5-HT2CR function. Using the imprinting centre deletion mouse model for PWS
(PWSICdel) we have previously shown impairments in a number of behaviours, some of which are abnormally sensitive to
5-HT2CR-selective drugs. In the stop-signal reaction time task test of impulsivity, PWS
ICdel mice showed increased
impulsivity relative to wild-type (WT) littermates. Challenge with the selective 5-HT2CR agonist WAY163909 reduced
impulsivity in PWSICdel mice but had no effect on WT behaviour. This behavioural dissociation in was also reflected in
differential patterns of immunoreactivity of the immediate early gene c-Fos, with a blunted response to the drug in the
orbitofrontal cortex of PWSICdel mice, but no difference in c-Fos activation in the nucleus accumbens. These findings
suggest specific facets of response inhibition are impaired in PWSICdel mice and that abnormal 5-HT2CR function may
mediate this dissociation. These data have implications for our understanding of the aetiology of PWS-related behavioural
traits and translational relevance for individuals with PWS who may seek to control appetite with the new obesity
treatment 5-HT2CR agonist lorcaserin.
Introduction
Prader–Willi Syndrome (PWS) is a neurodevelopmental disorder
caused by deletion or inactivation of paternally expressed
imprinted genes on human chromosome 15q11–q13 (1). The core
phenotypic features of PWS are severe neonatal hypotonia and a
failure to thrive in infancy, and the subsequent development of
hyperphagia and reduced satiety responses result in obesity,
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unless managed carefully (2). Additionally, individuals with
PWS also display a number of behavioural and cognitive
problems. These are manifest as a mild to moderate intellectual
disability with an average IQ of 60–80: impulsive and compulsive
behaviours, including increased rates of tantrums, opposition-
ality and aggression (3) and a particular cognitive deficit in
attention switching (4,5). Finally, a significant proportion of
individuals with PWS will develop a severe affective psychotic
illness (6). It is these behavioural and psychiatric problems
that are most difficult to manage and affect quality of life for
individuals and carers (7).
In the vast majority of cases of PWS, individuals have a
genetic or epigenetic abnormality that leads to complete loss of
all paternally expressed genes on 15q11–q13, including MKRN3,
MAGEL2,NDN,NPAP1, SNURF-SNRPN, the C/D box small nucleolar
(sno) RNAs SNORD109A, SNORD115 and SNORD116 (previously
termedHBII-438A,HBII-52 andHBII-85, respectively) and the non-
coding RNA IPW. However, rare clinical cases have narrowed the
critical PWS genetic interval to a region spanning the SNORD116
repeat and the IPW gene (8–10). The importance of this interval
is supported by animal studies showing paternal deletion of
Snord116 and Ipw leads to feeding, anxiety, sleep, growth and
metabolic phenotypes reminiscent of PWS (11–14). However,
although data is currently limited, deletion of Snord116 and
Ipw alone does not appear to contribute to other behavioural
and cognitive problems (15). In contrast, using the PWSICdel
mouse model, in which an imprinting centre (IC) deletion
results in complete loss of paternal gene expression at the PWS
interval, we have demonstrated a wide range of behavioural
abnormalities. In addition to feeding (16) and metabolic (17)
phenotypes, PWSICdel mice are hypoactive and show impaired
sensory-motor gating (18). Furthermore, PWSICdel mice show
a number of cognitive abnormalities, including enhanced
appetitive learning and reversal learning (19) and deficits in
visuo-spatial attention (18).
By using the PWSICdel mice we have also demonstrated
that abnormal post-transcriptional processing of the sero-
tonin 2C receptor (5-HT2CR) pre-RNA contributes to aspects
of these behavioural phenotypes (20,21). The 5-HT2CR pre-
RNA is subject to adenosine-to-inosine editing at five sites
within an alternatively spliced exon, exon Vb. Both of these
events result in less functional receptor moieties due to
their effects on the amino acid sequence of the critical G-
protein binding domain. Specifically, RNA-editing within exon
Vb leads to a change in codon-specificity and subsequent
amino acid sequence. Alternate splicing of exon Vb results
in a truncated protein lacking a functional G-protein binding
domain. Although this truncated splice variant cannot act
as a receptor, it plays a critical role in overall 5-HT2CR
function, by forming a heterodimer and sequestering the
full-length splice variant in the endoplasmic reticulum and
reducing cell surface expression (22). Processing of Htr2c pre-
RNA is mediated, in part, by the actions of the snoRNA
Snord115 (23–25), present within the imprinted PWS locus (26).
Expression of Snord115 is lost in PWSICdel mice (18), and there
are concomitant increases in 5-HT2CR RNA editing (21) and
splicing (20). Although loss of SNORD115 alone does not give
rise to PWS per se (27), PWSICdel mice demonstrate abnormal
5-HT2CR-mediated feeding (20), suggesting that this snoRNA
may contribute to the general PWS phenotype in those cases
where all paternal gene expression is lost (28).
The current study investigated the impact of abnormal
5-HT2CR functioning in PWSICdel mice on a key aspect of
cognition, namely response control. Specifically, we examined
the performance of the PWSICdel mice to inhibit a pre-potent
response in a stop-signal reaction time (SSRT) task. The SSRT
task (Fig. 1) is based on a ‘race’ between two response tendencies,
‘going’ and ‘stopping’ (29,30), where the subjects are trained to
make a rapid go response, between two stimuli locations, but
must withhold this response when a stop signal is presented.
The closer the stop signal is to the initial movement the easier
it is to stop the go response, and if the stop signal is presented
towards the end of the go response, stopping is much more
difficult. Performance of mice in the SSRTT is sensitive to
pharmacological manipulation of 5-HT2CR (31). We found that
PWSICdel mice displayed baseline (BL) deficits in the ability
to inhibit responding (i.e. increased impulsivity) compared to
wild-type (WT) littermate controls. Furthermore, administration
of a selective 5-HT2CR agonist had dissociable effects between
PWSICdel and WT mice, which was also reflected by specific
alterations in the pattern of neuronal activity, as measured by
c-Fos activation, in brain regions known to be important for
correct response control (32). These data suggest a psychological
basis to the impulsive/compulsive endophenotype shown by
PWS patients. This abnormal response control may bemediated,
in part, by aberrant 5-HT2CR functioning and therefore these
findings have translational relevance for individuals with PWS
whomay seek to control appetitewith the newobesity treatment
5-HT2CR agonist lorcaserin.
Results
No differences in shaping and training between WT
and PWSICdel mice
PWSICdel andWTmice were generated by crossing males positive
for the IC deletion with CD1 females and consistent with
previous studies (18,33), the PWSICdel mice were considerably
smaller than their WT littermates (31% and 30% lighter in
weight, for males and females, respectively), although this
size difference did not affect their propensity to consume
reward during habituation to the reinforcement (Table 1). The
majority of the mice were able to learn the SSRTT (Fig. 1),
passing through the different stages of shaping and training
(See Supplementary Material, Table S1); however, two WT and
two PWSICdel mice failed to reach criteria during training
and were therefore removed from the study leaving a final
N of 13 and 14 for the groups of WT and PWSICdel mice,
respectively (Table 1). There were no gender- or genotype-
related differences in the number of sessions taken to reach BL
SSRTT performance (Table 1), and there were also no differences
in the mean programmed go stimulus duration (main effect
of GENOTYPE, F1,23 = 3.64, P=0.08, η2 = 0.14) or time that the
mice were required to withhold a response in a stop trial to
earn reward (main effect of GENOTYPE, F1,23 = 1.16, P=0.29,
η2 = 0.05), key parameters which govern performance in the
SSRTT (Table 1).
PWSICdel mice show more impulsivity than WT
littermates in the SSRTT
All of the mice showed the anticipated increase in impulsive
responding as the stop-signal was moved closer to the end
of the go response, represented by the reduced ability to stop
and withhold responding (Fig. 2A, main effect of STOP-SIGNAL
POSITION, DELAY, F5,125 = 67.65, P=0.001, η2 = 0.73); however,
PWSICdel mice showed increased impulsivity relative to WT lit-
termate controls indicated by decreased proportion of correctly
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Figure 1. BL performance in the stop-signal reaction time task (SSRTT). Within each 100-trial session of the SSRTT, two types of trial were interpolated: go trials (80%,
A–C) and stop trials (20%,D–F). Subjects initiated a trial with a nose-poke response to the ‘initiation’ stimulus in the left-hand hole. (B) If the trial was a go trial, then the
go stimulus (light in right-hand hole) was illuminated, and a successful response at this location (C) would lead to delivery of 22 μL of the 10% condensed milk reward.
The duration that the go stimulus was illuminated for was titrated for each individual subject, and failing to make a go response was recorded as an omission and
resulted in 5 s time-out period signified by illumination of the house-light. Following collection of the reward, or a time out, the next trial was started by illumination
of the initiation stimulus. (D) Stop trials were also initiated by a left nose poke to the initiation stimulus, which also subsequently resulted in presentation of a light
in the right-hand hole (E). However, on these trials an auditory stop signal was also presented after trial initiation, instructing the mouse to inhibit responding to the
second stimulus. (F) Successful stopping resulted in reward delivery on these trials. In separate test sessions, the stop signal was presented at different positions into
a mouse’s individualized go reaction time, with early stop signals (0%) allowing for easier stopping, and later signals, close to the execution of the second stimulus
response (90%), making stopping more difficult. Failing to stop (i.e. making the second nose poke) resulted in 5 s time-out period and a new trial starting.
stopped trials (main effect of GENOTYPE, F1,25 = 4.74, P=0.04,
η2 = 0.16). A significant STOP-SIGNAL POSITION∗GENOTYPE
interaction (F5,125 = 2.38, P=0.04, η2 = 0.09) indicated that PWSICdel
mice differed fromWT, only when the stop-signal was presented
between 40% and 70%, or halfway through the individualized
go response (post hoc analysis for each stop-signal position:
40% P=0.002, 50% P=0.11, 60% P=0.033, 70% P=0.001), the
point where the stop and go processes are competing at their
greatest. There were no differences between PWSICdel and WT
mice in the number of correct go responses (Fig. 2B, main effect
of GENOTYPE, F1,25 = 1.36, P=0.25, η2 = 0.05), or in the speed of
making the go response (Fig. 2C, main effect of GENOTYPE,
F1,25 = 0.23, P=0.64, η2 = 0.01). Altering the stop-signal position
on ‘stopping’ were quite specific, as these manipulations did
not affect amount of (main effect of STOP-SIGNAL POSITION,
F5,125 = 0.40, P=0.85, η2 = 0.02), or the latency in these interpolated
go trials (main effect of STOP-SIGNAL POSITION, F5,125 = 1.19,
P=0.32, η2 = 0.05).
Examination of these effects further, by looking at the point
where the mice were making 50% correct stop responses (see
Materials and Methods), showed that for PWSICdel mice, the stop
signal was presented 30.4±5.5% into the go response, compared
with 46.7±6.6% for their WT littermates. At this point, the
SSRT, the virtual time take to decide to stop responding can be
calculated, which was significantly slower for PWSICdel mice in
comparison to WT (Fig. 2D, t25 = 2.38, P=0.025), consistent with a
pattern ofmore impulsive responding.Therewere no differences
between PWSICdel andWTmice for ancillary task measures, such
as the proportion of trials started (Fig. 2E, main effect of GENO-
TYPE, F1,25 = 0.14, P=0.71, η2 = 0.01), time taken to start a trial
(Fig. 2E, main effect of GENOTYPE, F1,25 = 2.56, P=0.12, η2 = 0.09)
or for the latency to collect the reward (Fig. 2E, main effect of
GENOTYPE, F1,25 = 1.85, P=0.19, η2 = 0.07), further demonstrating
the specificity of the effects on stopping.
The effects of gender on SSRTT performancewere also exam-
ined, especially in terms of interactions with the genotype of the
mice. Although, there were some significant effects of GENDER
and interactions between GENOTYPE and GENDER, these were
derived from differences between male and female WT mice
and there were no differences betweenmale and female PWSICdel
mice (See Supplementary Material, Table S1).
Effects of 5-HT2cR agonism on SSRTT performance
With increased alternate splicing (20) and RNA-editing (21) of
5-HT2CR RNA in the brains of PWSICdel mice, and the demon-
stration that manipulating 5HT2CR can affect stopping in the
SSRTT (31) we investigated whether PWSICdel mice would show
differential affects to WT in response to WAY163909, a specific
5-HT2CR agonist. The effects of WAY163909 were investigated
in sessions were the stop signal was placed at a point in the
individualized go responses where each mouse had shown 50%
correct stopping, i.e. the point where the go and stop responses
were equivalent. For the parameters analysed there were no
main effects of GENDER, or interactions between GENOTYPE and
GENDER in the initial ANOVA with a planned contrast to vehicle
treatment (See Supplementary Material, Table S2), therefore the
data were re-analysed without GENDER as a factor.
WAY163909 significantly increased the ability of PWSICdel
mice to withhold responding under conditions where stopping
was at 50% (Fig. 3A, main effect of GENOTYPE, F1,20 = 6.94,
P=0.016, η2 = 0.26). A significant interaction for the linear
contrast between DOSE and GENOTYPE (F1,20 = 6.09, P=0.023,
η2 = 0.23) demonstrated that this effect occurred only at the
higher does used, confirmed by post hoc comparisons between
WT and PWSICdel mice (t20 = 0.12, t20 = 0.02 and t20 = 0.014 at
the 0.1, 1 and 3 mg/kg doses, respectively). WAY 163909 at all
doses did not affect stopping behaviour in the WT mice, where
performance remained consistent with vehicle treatment.
WAY163909 did not significantly alter any other of the task
parameters and there were no genotype-related effects of the
drug at any dose on the SSRT (Fig. 3B, main effect of GENOTYPE,
F1,20 = 0.41, P=0.53, η2 = 0.02), proportion of go responding (Fig. 3C,
main effect of GENOTYPE, F1,20 = 1.65, P=0.21, η2 = 0.08), speed of
the go response (Fig. 3D, main effect of GENOTYPE, F1,20 = 0.66,
P=0.43, η2 = 0.03), proportion of trials started (Fig. 3E, main effect
of GENOTYPE, F1,20 = 1.09,P=0.31, η2 = 0.05), trial initiation latency
(Fig. 3F, main effect of GENOTYPE, F1,20 = 0.02, P=0.88, η2 = 0.01)
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Figure 2. Stop-signal reaction time task performance in PWSICdel mice. (A) Altering the position of the auditory stop-signal led to the anticipated increase in impulsive
responding as stopping was mademore difficult with presentations progressively closer to the execution of the go response. However, PWSICdel mice showed increased
impulsivity relative to WT littermate controls, particularly when the stop signal was presented near the middle of the individual go response. (B) Altering the position
of the stop signal did not affect the proportion of correct go responses made or the speed of the go response (C). However, there was a tendency for PWSICdel to make
more correct responses than their WT littermates. Further analysis of SSRTT performance was conducted to examine the point where competition between the go and
stop responding was at its greatest; thus, data from each subject were ranked and sessions where correct stopping was at 50± 10% averaged. When stopping with 50%
accuracy, the SSRT, the latency to withhold responding, was calculated (D). PWSICdel mice had significantly longer SSRTs than their WT littermates, but there were no
genotype-related differences for the proportion of trials initiated (E) and increases in the latency to initiate a trial (F) and the time taken to enter the food magazine
following a successful trial (G). Baseline data (BL: i.e. mean of the sessions immediately preceding each session where the stop-signal position was altered) when the
stop-signal presentation was concurrent with the start of the go response (0%). Data are mean±SEM, ∗ and ∗∗ denotes P < 0.05 and ∗∗P < 0.01 for significant difference
between WT and PWSICdel mice, respectively.
or the latency to collect the reward (Fig. 3G, main effect of
GENOTYPE, F1,20 = 0.13, P=0.83, η2 = 0.01).
Abnormal c-Fos immunoreactivity in PWSICdel mouse
brains
Injection of WAY163909 (1 mg/kg, i.p.) resulted in differential
effects on c-Fos reactivity between PWSICdel and WT litter-
mate mice that were specific to the brain regions analysed
(Fig. 4A and B). In the orbitofrontal cortex (OFC), the 5-HT2c
agonist significantly increased the number of c-Fos positive
cells (Fig. 4B, main effect of DOSE, F1,12 = 6.85, P=0.02, η2 = 0.36),
in both WT and PWSICdel mice (main effect of GENOTYPE,
F1,12 = 1.07, P=0.32, η2 = 0.08). However, this increase was greater
in WT mice (∼23% increase relative to ∼8% increase in
PWSICdel mice, t6 = 1.96, P=0.09), with only a significant increase
in c-fos reactivity in WT OFC samples (t6 = 2.84, P=0.03, cf.
PWSICdel: t6 = 0.84, P=0.44, for comparison between vehicle and
WAY163909 treatment). In the nucleus accumbens, there was
no effect of WAY163909 on c-Fos reactivity (Fig. 4C, main effect
of DOSE, F1,12 = 0.99, P=0.34, η2 = 0.08) in either PWSICdel mice
or their WT littermates (main effect of GENOTYPE, F1,12 = 0.06,
P=0.82, η2 = 0.01).
Discussion
We show that PWSICdel mice have impaired response inhibition,
as indicated by a reduced ability to stop in the SSRTT, and an
increased correct SSRT.Given previouswork indicating increased
alternate splicing and RNA-editing of Htr2c in the PWSICdel mice
and the role of 5-HT2CRs in response inhibition, we further
explored stopping performance by systemic administration of
a 5-HT2CR agonist (WAY163909). PWSICdel mice demonstrated an
abnormal response relative with WT littermate controls. This
behavioural response to 5-HT2CR agonism was also reflected
in blunted c-Fos activation in the orbital frontal cortex of the
PWSICdel mice following 5-HT2CR agonist. These data suggest
impaired response control,mediated in part by aberrant 5-HT2CR
functioning, could be a psychological basis to the impulsive/-
compulsive endophenotype shown by PWS patients.
Consistent with our previous studies (31,34), all mice
were able to complete the SSRTT and demonstrated the
expected patterns of behaviour, with stopping performance
systematically decreasing as the stop-signal moved closer to
the end of the go reaction time. There were no effects of stop-
signal position on the go correct rate, or correct go reaction time.
However, PWSICdel mice showed reduced response inhibition (i.e.
increased impulsivity) in the SSRTT as indexed by impaired
stopping accuracy and longer SSRT (the time taken after a stop-
signal is presented for inhibition to be completed), the standard
measure of response inhibition. SSRT cannot be measured
directly as there is no observable endpoint to the response
inhibition but is estimated using a well-defined and tested
mathematical model, the race model (30).
In addition to a BL measure of response control, we also
wanted to probe the function of the serotonin system in PWSICdel
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Figure 3. Effects of the 5HT2c agonist WAY163909 administration on stop-signal reaction time task performance in adult PWS
ICdel mice, injected at point where the
individual mice demonstrated 50% stopping. At all doses used, WAY163090 improved stopping performance in PWSICdel mice, but did not affect stopping behaviour of
WT littermates (A); however, the SSRT (B) was unaffected. The specificity of WAY163909 to affect stopping behaviour was shown by a lack of effects on the proportion
of correct go trials (C), speed of the go response (D), the proportion of trials performed (E), the latency to initiate a trial (F) and the latency to collect reward (G). Baseline
data (mBL: i.e. mean of the five sessions immediately preceding each drug treatment session) when the stop-signal presentation was concurrent with the start of the
go response (0%) are shown for illustrative purposes and were not included in the statistical analysis. Data showsmean±SE, ∗ denotes P<0.05 for compassion between
WT and PWSICdel mice.
Figure 4. Effects of the 5HT2c agonist WAY163909 administration on c-Fos immunoreactive cells in adult PWS
ICdel mice. c-fos reactivity was assessed in two brain
regions, the OFC and the nucleus accumbens (A). 1 mg/kg WAY163909 significantly increased the number of c-Fos positive cells in the OFC in WT, but not PWSICdel
mice (B). WAY163909 did not affect the number of c-Fos positive cells in the nucleus accumbens, for either WT pr PWSICdel mice (C). Data shows mean±SE. # denotes
P<0.05 for comparison of vehicle to WAY163909 for each group.
mouse model while performing the SSRTT. In particular, we
focused on the serotonin 2C receptor (5-HT2CR). This is because
post-transcriptional modification of Htr2c RNA is altered in the
brain of PWSICdel mice, with increased alternate splicing (20)
and RNA-editing (21), most probably as a consequence of loss
of brain-specific snoRNA snord115 in this model. Furthermore,
there is a known role for 5-HT2CR in stopping behaviour, as
response control is improved by the 5-HT2CR-specific antagonist
SB242084 in the SSRTT (31). Here we employed the use of the
5-HT2CR-specific agonist WAY163909 and saw a divergence in
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effects on stopping behaviour between WT and PWSICdel mice.
Specifically, following WAY163909 administration WT mice
showed some reduction in performance but were generally
unaffected by the drug, whereas PWSICdel mice displayed a
marked improvement in stopping behaviour. Although not as
clear-cut, this pattern of effects is very similar to those seen
on feeding behaviour, where 3 mg/Kg WAY163909 inhibited
feeding in WT mice, but enhanced feeding in PWSICdel mice
(20). Moreover, this apparent opposite effect of WAY163909
administration, decreasing impulsivity in the SSRTT and
increasing feeding,may be a result of effects of 5-HT2CR agonism
in different parts of the brain with distinct dissociable functions
on behaviour. However, a recent study (35) has demonstrated
that agonism of the 5-HT2CR withWAY163909, affected response
control, akin to the improved stopping we have found here,
in combination with consumption of a high calorific diet
suggesting a relationship between dietary habits and decision-
making strategies with 5-HT2CR at the nexus (36,37).
The pattern of findings of impaired response control
on the SSRTT contrasts with previous findings in the five-
choice serial reaction time task (5-CSRTT), where PWSICdel mice
exhibited no differences in premature responding (21). The
5-CSRTT is primarily used tomeasure visuospatial attention, and
indeed PWSICdel mice were found to be impaired in attentional
function (18). However, premature responding in the 5-CSRTT is
also a measure of response inhibition (38). Why PWSICdel mice
show BL deficits in one task and not the other could be due
two possible reasons. First, it could be that PWSICdel mice are
generally impaired in response control, but that the tasks are
not equivalent in terms of difficulty and so BL deficits only
emerge on the more demanding SSRTT where the inhibitory
load is highest (39). Alternatively, the PWSICdel mice may be
more impaired in a specific aspect of response control. It is
now established that response control can be dissociated into
a number of psychologies that are also neurally distinct (40,41).
This is certainly the case for the SSRTT and the 5-CSRTT that
measure the ability to cancel an ongoing action (‘stopping’)
and the ability to inhibit the initiation of an action (‘waiting’),
respectively.Our data would therefore suggest that PWSICdel mice
are more impaired at stopping (an ongoing action), something
that could, in part, be due to the differential influence of less-
functional 5-HT2CRs in this model.
To further explore the idea that 5-HT2CR function varies
in the PWSICdel mice, we also examined c-Fos activity in the
brain following administration of 1 mg/Kg WAY163909. This
dose was selected as it resulted in the biggest divergence in
stopping behaviour between PWSICdel and WT mice. Thus, fol-
lowing drug treatment, PWSICdel mice showed reduced c-Fos
immunoreactivity in the OFC, an area that is important for
‘stopping’ behaviour (42) but not in the nucleus accumbens, an
area that is less critical for inhibitory behaviour in the SSRTT
(43,44). This blunted engagement of OFC c-Fos neurons may be a
reflection of diminished activation of 5-HT2CR in PWSICdel mice,
as a result of a decrease of the most active 5-HT2CR isoforms in
this area. Regional variation in the degree of post-transcriptional
modification, giving rise to differential sensitivity and activation,
has been reported in the rat brain (45), and it may well be that
this is reflected in variability of 5-HT2CR isoform expression, and
therefore drug sensitivity, in PWSICdel mice. Regional variation in
5-HT2CR functionality, and recruitment of different brain regions
implicated in response control,may also account for the dissoci-
ation in altered impulsive responding in PWSICdel mice between
the current data using the SSRTT, and previous findings in the
5-CSRTT (18).
Taken together with previous findings, this study suggests
that response control is compromised in PWSICdel mice. This
cognitive deficit may underpin some of the behavioural charac-
teristics seen in PWS, such as temper tantrums, stubbornness
and compulsive behaviour (3). The work also adds to the bur-
geoning literature suggesting that 5-HT2CR function is impaired
in the PWSICdel mice (20,21). The most logical explanation for
this is alteration in alternate splicing and/or editing of 5-HT2CR
pre-mRNA due to loss of expression of the imprinted regulatory
snoRNA snord115 (20,21,23). However, it should also be noted
that serotonin neurochemistry is also altered in mice that lack
the PWS imprinting locus genes Necdin (46) or Magel2 (47) alone.
Nevertheless, the specificity of some the effects demonstrated
here and previously (21) indicates these are not just generalized
abnormalities due to serotonin imbalance but are due, in part,
to global impairments in 5-HT2CR function in the PWSICdel mice.
With the introduction of 5-HT2CR agonists, such as lorcaserin,
to control appetite and act as anti-obesity treatments (48), our
results have translational implications for treatment of individ-
uals with PWS. As demonstrated in our current and previous
studies (e.g. 21), using 5-HT2CR agonists may produce differen-
tial effects in PWS patients to non-affected people, therefore
management of PWS-related dietary issues using these drugs
may not be less affective and alternative therapeutic pathways
may need to be pursued.
Materials and Methods
Subjects
Sixteen PWSICdel and fifteen WT littermates adult mice, aged
∼4 months old at the start of the experiment were used. Mice
were obtained from breeding males positive for the IC deletion
with CD1 females, which generated paternally derived mutants
and WT littermates; the nature of the epigenetic regulation of
imprinted genes means that a paternally inherited IC deletion
will result in a lack of gene expression from the PWS interval. As
previously described (18,21,33) breeding to a C57BL/6 J∗CD1 back-
ground reduces the risk of postnatal lethality in PWSICdel mice;
however, to increase yield excess WT pups in each litter were
culled (identified on the basis of their increased size 48 h after
birth) leaving only one or two per litter. However, evenwith these
measures in place, both male and female mice were used to
generate a viable amount of PWSICdel mice for the current study,
housed in separate sex litters with two to three animals each. All
subjects were housed in a vivarium with environmental control
(temperature: 21±2◦C, humidity 50±10%) and a 12:12 light/dark
cycle (lights on at 07:00 hr). Following 2 weeks of habituation
and handling, a home cage water and food restriction sched-
ule was introduced systematically for over a further 2 weeks.
For the duration of the experiment the mice received access
to water and food for 2 and 8 h access/day, respectively. This
regime maintained the subjects at ∼90% of free-feeding body
weight and motivated the animals to work in the task. All pro-
cedures were conducted in accordance with the requirements
of the UK Animals (Scientific Procedures) Act 1986 and with
local institute approval from the School of Psychology, Cardiff
University.
Apparatus
The SSRTT was performed in mouse nine hole chambers (31,49)
(Campden Cognition, UK) with the task under the control of
custom written software. Each test chamber (14 × 13 cm) was
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enclosed in a sound attenuating box equipped with a fan to
provide ventilation and also a consistent level of background
noise. The test chamber was equipped with nine circular
response apertures (10 mm diameter) arranged in an arc on
the back wall. Each aperture was configured with a vertically
orientated infrared beam and a 40mA stimulus light at the distal
end. For the SSRTT the stimulus array was configured such that
only two of the stimuli apertures were open (the others were
blocked by black plastic). The open apertures, holes number 3
and 7 (from the left), were equally placed relative to the centre
line of the chamber and were designated as the initiation and
go responses, respectively. The near wall, including the access
door, held the food magazine (2 cm wide) that was enclosed
by a clear Perspex door and could also be illuminated by a
60 mA lamp. Opening of the food magazine door was recorded
by the triggering of a micro-switch, as panel pushes. Reward was
delivered into a small well in the floor of the foodmagazine via a
21-gauge hypodermic needle and 0.8-mm silicone tubing from a
peristaltic pump located outside of the test chamber but within
the sound attenuating box. A 60-mA house light and speaker
were fitted to both side walls of the test chamber and a pair of
infrared beams which spanned the chambers, perpendicular to
the stimulus array and 5 mm above the grid floor, were used to
recordmotor activity. An infrared camera (Watac, USA) mounted
inside the sound attenuating box permitted observation and
recording of behaving mice. The white noise stop signal, 105 db,
was provided by a custom built sound generator.
SSRTT: initial shaping and training to BL
After the 2 weeks on the home cage water and food restriction
schedule, the mice were habituated to the liquid reward to
be used in the experiments, 10% condensed milk (Nestle Ltd,
UK) solution, using methods employed previously (31,49). All
sessions in the nine-hole boxes were performed with the house
light off. The subjects were first habituated to the chambers for
3 days before training to the BL SSRTT (Fig. 1), which involved
shaping the mice to respond sequentially at two stimulus loca-
tions, using nose pokes, to give rise to a ‘go’ response, and then
learning to withhold responding to the second stimulus location
when an auditory stop signal was presented, to give rise to
a ‘stop’ response (see Supplementary Material, Fig S1). During
training, the duration of the go stimulus, and the time that a
response had to be withheld in a stop trial, were determined
individually for each subject. In an SSRTT session (≤20 min
session duration), there was amaximum of 100 trials,where 80%
of trials were ‘go’ trials and 20% were interpolated ‘stop’ trials
(Fig. 1).
SSRTT; behavioural manipulations
At BL, in ‘stop’ trials, the stop signal was always presented
coincident with the beginning of the go response (i.e. 0% of
the individual correct go reaction time for each subject), mak-
ing stopping relatively easy, but in separate probe sessions the
position of the stop-signal was varied relative to the individual
correct go reaction times for each mouse making stopping more
or less difficult i.e. at 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%
and 90% into the individualized go reaction time for eachmouse.
At 90%, the stop signal was played close to the execution of
the response, and hence stopping was most difficult (31,50). The
order of presentation of these sessionswas randomized between
subjects using a Latin square design.
Pharmacological administration for assessing SSRTT
performance
The effects of the 5-HT2CR agonist WAY163909 ((7bR,10aR)-
1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,
7,1hi]indole) (Sigma, UK) on SSRTT performance in WT and
PWSICdel mice were investigated using doses shown previously to
have a biological effect in rodents (0, 0.1, 1 and 3 m/kg, (20,51)).
Following at least 4 days of stable drug-free performance at BL
SSRTT criteria (i.e. stop-signal position of 0%), intraperitoneal
injections of vehicle or WAY163909 (0.1, 1 and 3 m/kg) made up
freshly on the day of use as freebase in physiological saline were
administered 30 min before testing following a Latin square
design. Drug treatment was given in combination with SSRTT
sessions where the stop-signal was presented at a position that
had given rise to 50% correct stopping for each subject, thus
individual stop-signal positions were employed for each subject.
For these studies 10 WT and 12 PWSICdel mice from the original
cohort were used.
Pharmacological administration for assessing c-Fos
reactivity
On completion of the behavioural study, some of the WT and
PWSICdel mice were randomly assigned to receive either vehicle
or 1 mg/kg WAY163909 i.p. treatment (four subjects/treatmen-
t/genotype, see Table 1) 90 min prior to sacrifice. During this
interval, the animals remained uninterrupted in their home cage
to permit optimum c-Fos expression. They were then deeply
anaesthetized with Euthasol (100 mg/kg, i.p.) and perfused tran-
scardiallywith 50mL of ice-cold 0.1Mphosphate-buffered saline
(PBS), pH 7.4, followed by 100mLof 4%paraformaldehyde in 0.1M
PBS, pH 7.4. The brains were then removed, postfixed overnight
at 4◦C in 4% paraformaldehyde, and then transferred to 30%
sucrose for 24 h while continuously being stored at 4◦C. Coronal
sections (40 μm) were collected using a freezing microtome then
stored at −20◦C in a cryoprotectant solution until required. Sec-
tions were first incubated in rabbit anti-Fos polyclonal antibody
(ABE457; 1:3000; Merck) for 24 h at 4◦C. Sections were then rinsed
in TBST (3×10 min) containing 3% NGS, then incubated in Tris
buffered saline with Tween-20 (TBST) containing biotinylated
goat anti-rabbit IgG (1:100; Vector Laboratories) and 3% NGS for
1 h and then rinsed in 0.1 M TBST (3× 10 min). After which
sections were incubated for 1 h in ABC complex (Vectastain
Elite ABC Kit; Vector Laboratories), then washed in 0.1 M TBST
(3×10 min), then washed in 0.05 M Tris buffer (2× 10 min).
Sections were then incubated in DAB solution (DAB Peroxidase
(HRP) Substrate Kit (with Nickel), 3,3′-diaminobenzidine; Vector
Labs) for ∼30 s. Sections were then mounted onto subbed slides,
dried and dehydrated before cover slipping. Regions of interest,
the OFC and nucleus accumbens, were selected according to a
mouse stereotaxic atlas of the brain (52) (Fig. 4A and B). Three
sections per brain region per animal were counted and averaged
to give number of Fos positive cells within an area of 0.6 mm2 at
10× magnification using the Image J analysis program (version
1.43q, NIH, USA).
Statistical analysis
The main measures from the SSRTT were the proportions of
correct stopping and going, the correct go reaction time, the trial
initiation latency, proportion of trials started and the reward col-
lection latency. Ancillary measures of general task performance,
including the numbers of food magazine entries, initiation and
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go nose-pokes and locomotion measured as beam break were
also assessed. SSRTs in the task were estimated employing the
standard procedure described in Logan et al. (30), using data from
where the proportion of correct stop responses is ∼50%. For
each subject, data from the sessions in which the stop-signal
positions were varied relative to the individualized go reaction
time, were ranked by the proportion of correct stop responses,
and data from sessions in which this value was between 40%
and 60% (i.e. 50%±10%) were averaged. The latency of stopping
as defined by the SSRT was derived from the distribution of
correct go reaction times and the proportion of correctly stopped
trials as previously described (29,53). Hence, for each of the
sessions determined above, the correct go reaction times were
rank ordered from smallest to largest and the nth value found,
where n is the rank order position based on the proportion of fail-
ing to stop correctly in stop trials, corrected for the occurrence
of omitted go trials (53–55). To determine the SSRT, the time the
stop signal was presented (i.e. ‘mean correct go reaction time’
× ‘% mean stop-signal position’) was subtracted from the nth
correct go reaction time value. Scores calculated as percentages
were arcsine, and latencies square root transformed prior to
analysis.
Datawere analysed using SPSS (V.20, SPSS Inc,USA), andwere
first assessed for normality, and then subjected to two-tailed
t-test or ANOVA, if appropriate or equivalent non-parametric
analyses, and where sphericity assumptions were violated,
Greenhouse–Geisser corrections were used. As both male and
female mice were used in these experiments, all data was
subjected to an initial analysis that included GENDER as a
between-subjects factor; however, if this was non-significant
then a further analysis was conducted without this factor. The
total volume consumed/bodyweight0.75 and reward preference
from reward consumption test were assessed by ANOVAs
with between subjects factor of GENOTYPE (WT, PSWICdel) and
GENDER, and within subject factor of SESSION (Days 1 through
7), and the number of sessions taken to shape and train themice
in the SSRTT by unpaired two-tailed t-tests. SSRTT parameters
were analysed by separate ANOVAs with between-subject
factors of GENOTYPE and GENDER and within-subjects factor of
STOP-SIGNAL POSITION (0 (mean BL), 10%, 20%, 30%, 40%, 50%,
60%, 70%, 80%, 90%) and STOP-PERFORMANCE (mean BL, 50%
correct stopping). The effects of WAY163909 were analysed by
ANOVA with between subject factors of GENOTYPE and GENDER
and within-subjects contrasts factor of DOSE (vehicle, 0.1, 1
and 3 mg/kg), with vehicle as the planned contrasting level.
For the analysis of c-Fos reactivity, separate two-way ANOVA
were conducted for each brain region investigated,with between
subject factors of GENOTYPE and DOSE (vehicle, 1 mg/kg
WAY163909) were used. If a significant difference was found,
then post hoc pairwise comparisons were performed using t-
tests or Bonferroni tests, and adjusted for multiple comparisons.
Criterion level of significance was set at the 0.05 level. All data
are shown as mean± standard error of the mean (S.E.M.).
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Supplementary Material is available at HMG online.
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